# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
The partnership, initiated in 2009, supported Bio-Manguinhos/Fiocruz with reagents and instruments for testing samples for HIV ...
This collaboration represents a significant milestone as the QIAstat-Dx panel would be the first commercially available IVD for...
QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA)))) today announced the expansion of its Master Collaboration Agreement with A...
Baird analyst Catherine Schulte maintains Qiagen (NYSE:QGEN) with a Outperform and raises the price target from $49 to $52.
QIAGEN has updated its FY 2024 outlook based on the solid core business performance in the first half of the year, which was ab...
Qiagen (NYSE:QGEN) reported quarterly earnings of $0.55 per share which beat the analyst consensus estimate of $0.51 by 7.84 pe...
QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA)))) today announced a partnership with the Snow Molecular Anthropology Lab at ...
Wolfe Research analyst Doug Schenkel upgrades Qiagen (NYSE:QGEN) from Peer Perform to Outperform and announces $50 price tar...
The FDA granted accelerated approval to Bristol Myers Squibb's Krazati (adagrasib) with cetuximab for adult patients with K...